Kyle VanKoevering

Dr. Kyle VanKoevering


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Oral Oncology
Verified
Journal Article
Closed access
SNSarah C. Nyirjesy
Sarah C. Nyirjesy
MHMargaret Heller
Margaret Heller
NWNatalia von Windheim
Natalia von Windheim
AGAmelia Gingras
Amelia Gingras
SKStephen Y. Kang
Stephen Y. Kang
KVKyle VanKoevering
Kyle VanKoevering

6 July 2021 in Journal of Materials Research
Verified
Journal Article
Closed access
PDF file
GDGeorges E. Daoud
Georges E. Daoud
DPDante L. Pezzutti
Dante L. Pezzutti
CDCalvin J. Dolatowski
Calvin J. Dolatowski
RCRicardo L. Carrau
Ricardo L. Carrau
MPMary Pancake
Mary Pancake
KVKyle VanKoevering
Kyle VanKoevering

1 January 2021 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
JMJustine Moe
Justine Moe
JFJessica Foss
Jessica Foss
RHRachel Herster
Rachel Herster
CPCorey Powell
Corey Powell
JHJoseph Helman
Joseph Helman
KVKyle VanKoevering
Kyle VanKoevering

3 February 2019 in Journal of Neurological Surgery Part B: Skull Base
Verified
Journal Article
Closed access
PDF file
KVKyle VanKoevering
Kyle VanKoevering
KSKatayoon Sabetsarvestani
Katayoon Sabetsarvestani
SSStephen E. Sullivan
Stephen E. Sullivan
ABAriel Barkan
Ariel Barkan
MMMichelle Mierzwa
Michelle Mierzwa
EMErin L. McKean
Erin L. McKean
Background Management of anterior cranial base malignancies requires multidisciplinary care. Radiation therapy remains a mainstay of definitive or adjuvant treatment. Apart from primary hypothyroidism, the effects of radiation on the hypothalamic–pituitary axis after high-dose treatment of head and neck malignancies remain poorly described. We describe a comprehensive screening protocol for surveillance and characterize the incidence of pituitary dysfunction after radiation for anterior cranial base malignancies. Methods A review of patients prospectively enrolled in a skull base registry at an academic center was performed. Included patients had a history of anterior skull base malignancy and external beam radiation to the primary site, with comprehensive post-treatment pituitary serologies and at least 1 year of post-radiation follow-up. Routine hormonal screening was initiated during the study period for all patients with anterior skull base irradiation. Results Eighty-one patients met inclusion. Fifty-eight patients (71%) demonstrated some laboratory abnormality. Thirty patients (37%) demonstrated evidence of hypopituitarism. Twenty-four (29%) demonstrated central hypogonadism, and 16% of patients showed central hypothyroidism. Ten patients (12%) displayed central adrenal insufficiency with six patients demonstrating panhypopituitarism. Primary tumor location and maximum dose of radiation to the gland appeared to correlate with incidence of hypopituitarism. Conclusion Radiation for malignancies of the anterior skull base resulted in a 37% incidence of hypopituitarism in our study. Given the potential morbidity of hypopituitarism, we recommend annual post-treatment screening in these patients. We describe a comprehensive set of serologies that can be utilized, and recommend updating clinical guidelines to reflect the necessity of this screening.

17 July 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
RGRebecca W. Gao
Rebecca W. Gao
DRDeborah Rooney
Deborah Rooney
RHRebecca Harvey
Rebecca Harvey
KMKelly M. Malloy
Kelly M. Malloy
KVKyle VanKoevering
Kyle VanKoevering

6 January 2022 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
ANAkash N. Naik
Akash N. Naik
DSDustin A. Silverman
Dustin A. Silverman
CRChandler J. Rygalski
Chandler J. Rygalski
SZSongzhu Zhao
Songzhu Zhao
GBGuy Brock
Guy Brock
SKStephen Y. Kang
Stephen Y. Kang